Public Research Library
Specialties:
Most Popular Reports:
- Laser Body Sculpting SmartLipo-Trends in Use
- Essure Permanent Birth Control
- Oral Contraceptives Market Evaluation
- Trends and Forecast of Dental Implant Cases
- Avastin and the AVADO Trial Survey
Newest Reports:
Anti-Anginal Medication: Ranexa™ Trends in Use
A Survey of One Hundred Two Cardiologists and Primary Care Physicians
Study Description
|
Topic |
Anti-anginal therapeutic market and Ranexa™ usage and impressions |
|
Respondent Type |
Physicians |
|
Specialty |
Cardiology, Primary care |
|
Region |
United States only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website § Duration: 20 minutes § Size: 102 respondents § Fielding dates: July 11 to July 17, 2007 |
Study Objectives
To clarify current usage patterns and potential for the CVTX’s anti-anginal medication Ranexa™ (ranolazine). A survey of cardiologists and primary care physicians was conducted to:
§ Quantify current and future applications of Ranexa™ and determine market shares among therapeutics currently used to treat chronic angina pectoris.
§ Understand drivers of physician prescribing practices, especially with regard to facilitators and barriers to use of Ranexa™ (clinical data, treatment guidelines, cost, insurance coverage, others).
§ Determine the potential impact of a large-cap pharmaceutical partner on Ranexa™ prescribing volumes among primary care physicians and cardiologists.
§ Determine awareness and impact on prescription patterns, if any, of the MERLIN-TIMI 36 Randomized Trial on Ranexa™ (data published in the Journal of the American Medical Association in April 2007).
Companies Mentioned in This Report
|
Company |
Ticker |
Product |
|
CV Therapeutics |
CVTX |
Ranexa™ |
Inclusion Criteria and Respondent Demographics
|
Inclusion Criteria |
§ Board-certified or eligible cardiologists and primary care physicians (PCPs) with 2 to 30 years of experience post-residency § Minimum of 75% professional time spent in clinical practice § Currently manages at least 25 patients with chronic angina pectoris and writes at least 10 prescriptions for anti-anginal medications on average per month § Has prescribed Ranexa™ for any use in the last month (cardiologists) or is aware of Ranexa™ as a cardiovascular agent to treat angina (PCPs) |
Reports become free one year after the publication date.
 about us contact us |
 |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |